Multi-Target CAR-T Cells for Solid Tumors
Multi-target CAR-T cell trial for solid tumors. Advanced dual-targeting therapy for EGFR and HER2 positive cancers.
Phase I/II Study of Multi-Target CAR-T Cells for Solid Tumors
Full Title
A phase I/II, open-label, dose-escalation and expansion study of dual-target chimeric antigen receptor T-cells targeting EGFR and HER2 in patients with advanced solid tumors expressing these antigens
Purpose
Regular CAR-T cells target one protein on cancer cells, but cancer can escape by losing that protein. This study tests CAR-T cells that target two different proteins at once (EGFR and HER2), making it much harder for cancer cells to escape.
Primary Objectives
- Determine the safety and maximum tolerated dose of dual-target CAR-T cells
- Evaluate CAR-T cell persistence, expansion, and trafficking to tumor sites
- Assess preliminary antitumor activity and disease control rate
Diseases
Who Can Join this Trial
To participate in this study, you must meet ALL of the following criteria
- Have histologically confirmed advanced or metastatic solid tumor cancer
- Tumor must express EGFR and/or HER2 by immunohistochemistry
- Have received at least one prior line of standard systemic therapy
- Have progressive disease within 6 months of last therapy
- Have at least one measurable lesion per RECIST v1.1
- ECOG performance status 0-2
- Age 18-75 years
- Life expectancy ≥12 weeks
- Adequate organ function including blood counts and heart function
- No active autoimmune disease requiring systemic immunosuppression
Access Clinical Trials
Locations
CONTACT
📞 Call Now: 1-800-NEOVITA (1-800-636-8482)
🌐 Online Scheduling: Schedule Your Consultation
📧 Email: info@neovitaoncology.com